Skip to main content

Advertisement

Table 2 A570 values of different treatments when adding drug firstly (n = 6)

From: Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes

GP Concentration (μg/mL) A 570 Hepatocyte protection rate rate (%) pGP Concentration (μg/mL) A 570 Hepatocyte protection rate rate(%)
100 0.351 ± 0.007b 48.17 25 0.405 ± 0.007a 93.55
50 0.298 ± 0.007c 20.42 12.5 0.306 ± 0.006b 40.32
25 0.274 ± 0.012cd 7.85 6.25 0.297 ± 0.008b 35.48
12.5 0.285 ± 0.007cd 13.61 3.125 0.276 ± 0.009c 24.19
6.25 0.279 ± 0.011cd 10.47 1.5625 0.269 ± 0.006c 20.43
0(VC) 0.259 ± 0.012d   0(VC) 0.231 ± 0.007d  
0(CC) 0.450 ± 0.009a   0(CC) 0.417 ± 0.008a  
  1. a-dData in same column without same superscript (a–d) differ significantly(p < 0.05)
  2. GP Gypenoside, pGP phosphorylated gypenoside, VC virus control, CC cell control